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Abstract
Background: With increasing experience using anti-VEGF therapy for the treatment of neovascular age-related
macular degeneration (nAMD), ophthalmologists have shifted away from a “one size fits all” to an “individualised”
approach based on disease activity with the aim of achieving a fluid-free retina. The FLUID study investigates the
non-inferiority of a Treat and Extend (T&E) protocol of 0.5 mg ranibizumab, which allows treatment extension in the
presence of incomplete resolution of sub-retinal fluid (SRF) ≤200 μm at the foveal centre relative to a T&E protocol
that requires complete resolution of all retinal fluid (i.e., both SRF and intra-retinal fluid [IRF]) in patients with nAMD.
Methods/Design: This 24 month, randomised, phase IV trial has completed recruitment of treatment-naïve patients
randomised 1:1 to ranibizumab “intensive” treatment (complete resolution of IRF and SRF) or ranibizumab “relaxed”
treatment (resolution of IRF or >200 μm SRF only at foveal centre). Patients in both arms follow a T&E regimen
where extension decisions are based upon assessment of lesion activity: loss of ≥5 letters of visual acuity, new
haemorrhage, presence of IRF and SRF on an optical coherence tomography (OCT) scan. The determination of SRF
is conducted at a reading centre while the assessment of IRF is physician-determined. The primary endpoint is the
mean change in best-corrected visual acuity (BCVA) from baseline to 24 months. Secondary endpoints include the
mean change in central retinal thickness (CRT) from baseline to 12 and 24 months, the number of ranibizumab
injections administered at 12 and 24 months, and the pharmacogenomic assessment of AMD Gene Consortium-
identified single-nucleotide polymorphisms (SNPs) and their association with treatment response. Three hundred
and forty seven (347) patients have been recruited by 16 Australian sites within approximately 16 months. A
protocol to adjudicate on SRF has been established by the central reading centre and is demonstrating good
concordance with investigator assessment.
Discussion: This study will provide important insights into retreatment criteria for managing nAMD using a T&E
regimen. The current paper describes the clinical rationale for using a less intensive treatment approach using
ranibizumab and details of the treatment protocol.
Trial registration: Trial registration number: NCT01972789. Date of registration: 24th October 2013.
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Background
The advent of anti-vascular endothelial growth factor
(VEGF) designed for intraocular injection has revolutio-
nised the treatment of neovascular age-related macular
degeneration (nAMD), the leading cause of severe vision
loss in the elderly population. Coupled with diagnostic
advances and improvements in monitoring, anti-VEGF
therapy has contributed significantly to a decrease in
cases of blindness, improvement in patient quality of life,
and overall public health expenditure on the conse-
quences of vision loss [1].
The pivotal trials of ranibizumab (Lucentis), MARINA
[2] and ANCHOR [3], investigated the efficacy and
safety of monthly injections on visual acuity, thus this
treatment regimen subsequently formed the basis for its
initial registration indication [4]. With the evaluation of
different injection regimens through subsequent pro-
spective clinical trials (PIER, EXCITE, SUSTAIN) and
increasing clinical experience by ophthalmologists, it be-
came clear that less frequent ranibizumab injections
could yield visual benefits in certain subgroups of pa-
tients comparable to those of monthly injections [4–10].
In the randomised, controlled trial CATT, which evalu-
ated monthly monitoring and a pro re nata (PRN) or ‘as
needed’ treatment approach with anti-VEGF therapy,
PRN ranibizumab treatment was observed to be non-
inferior to monthly ranibizumab in terms of visual out-
come at one year, but reduced the number of injections by
almost one-half, although the second year results demon-
strated a greater gain in visual acuity with monthly injec-
tions relative to PRN for both ranibizumab and
bevacizumab treatments (p = 0.046 for regimen) [11, 12].
A similar outcome to that of the CATT one year results
was observed in the HARBOR study, although the pre-
specified non-inferiority comparison was not met for the
0.5 mg ranibizumab PRN dose [13]. Individualised
approaches, requiring the determination of disease activ-
ity, is now widely used in protocols using all anti-VEGF
agents.
A modified PRN approach, which is more proactive, is
termed Treat and Extend (T&E); with this, patients re-
ceive a mandatory injection at each visit but the interval
for the subsequent visit is determined by the clinician’s
assessment of the disease activity. Generally, the exten-
sion interval for such a protocol is 2 weeks and the
retreatment criteria is based on, among other morpho-
logical and visual indices, resolution of all SRF and IRF.
A number of retrospective/observational and prospective
studies in which a T&E protocol has been implemented
have reported visual gains of, on average, 9.6 letters
(range: 7–11 letters across cited studies) in the first year
of treatment and 8.7 letters (range: 8–9.2 letters across
cited studies) in the second year of treatment [14–18].
These outcomes have been achieved with an average of
8.1 injections in the first year of treatment and 6.3 injec-
tions in the second year of treatment. In all studies
cited above, patients were treated with ranibizumab
0.5 mg (with the exception of one study in which
27 % patients were treated with bevacizumab) and the
physicians all treated with the goal of achieving a dry
retina (retinal fluid was a key retreatment criterion).
These outcomes are comparable to those described in
large, real-life, observational studies of anti-VEGF therapy
in nAMD patients [19, 20].
The definition of disease activity has historically been
based upon three parameters: a loss of ≥5 letters in vis-
ual acuity (VA), evidence of new haemorrhage and the
presence of intra-retinal fluid (IRF) and sub-retinal fluid
(SRF) as determined on an optical coherence tomog-
raphy (OCT) scan [21]. Parameters of choroidal neovas-
cularisation (CNV) activity on OCT scanning have
developed and refined with improvements in OCT tech-
nology and clinical experience. Most individualised or
PRN treatment regimens, including those used to guide
treatment in the CATT [11, 12] and HARBOR [13] clin-
ical trials plus the T&E studies described above [14–18],
aim to completely resolve all IRF and SRF to achieve a
“dry” retina as seen on OCT scanning. However, it is
not known if all “fluid”, as determined by dark empty
spaces on the OCT, truly indicate ongoing disease
activity and, as such, whether their presence should
always mandate an “active disease” response leading
to a change in interval duration.
To date, there is poor correlation between VA outcomes
and the fluid status of the retina. The CATT 2 year results
revealed that a doubling of the proportion of patients who
achieved a dry retina (ranibizumab PRN arm: 22.3 % pa-
tients vs. ranibizumab monthly arm: 45.5 % patients) did
not equate to any change in the proportion of patients
who gained 15 letters or more (ranibizumab PRN arm:
30.7 % patients vs. ranibizumab monthly arm: 32.8 %
patients) [12]. Similarly, the 96 week VIEW [22] study
results revealed little difference in the proportion of pa-
tients who gained 15 letters or more (ranibizumab
monthly arm: 34.9 % patients vs. aflibercept monthly arm:
29.4 % patients) or the number of letters gained (ranibizu-
mab monthly arm: 9.4 letters vs. aflibercept monthly arm:
7.6 letters) in spite of a notable difference in the propor-
tion of patients achieving a dry retina (ranibizumab
monthly arm: 60.4 % patients vs. aflibercept monthly arm:
80.3 % patients) [22].
Currently, it is not known whether it is imperative to
resolve all of both IRF and SRF to achieve best results. It
may be possible to allow some SRF to remain and to
continue extending the treatment interval without any
detriment to the long term visual outcome. It is possible
that, in some cases, the SRF simply reflects the topog-
raphy of the retina and underlying structures where
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there is a “gap” between peaks of drusen and retinal
pigment epithelium (RPE) and the overlying retina; it
may not be an indication of ongoing neovascular disease
activity. Indeed, a study of 214 eyes that received anti-
VEGF therapy for the treatment of nAMD demonstrated
that the combined presence of IRF and SRF at baseline
lead to worse presenting visual acuity (20/120) compared
to the presence of SRF only (20/72). At the end of three
consecutive monthly loading doses of anti-VEGF ther-
apy, eyes with residual IRF (in combination with SRF)
averaged 20/180 while eyes with no fluid (either SRF or
IRF) averaged 20/80 (p = 0.05) which was comparable to
eyes with SRF alone (20/90). While this study strongly
suggests that fluid may be a predictor of visual outcomes
in patients treated with anti-VEGF therapy, this does not
discount the potential role of other factors, such as fi-
brosis, atrophy and subretinal hyper-reflective material
(SHRM), in predicting response.
One consequence of insisting upon complete lack of
IRF and SRF is a greater injection frequency, with the
inherent risks associated with injections of drug into the
vitreous cavity, both ocular (such as endophthalmitis,
lens trauma and retinal detachment) and potentially any
systemic events. An additional consequence of greater
injection frequency is the potential for earlier progres-
sion of macular atrophy (also termed geographic atrophy
in the literature), which has been hypothesised as being
exacerbated over time with intensive, long-term anti-
VEGF therapy. The CATT study [12] 2 year results re-
vealed a 59 % increase in the risk of geographic atrophy
with 2 years of monthly injections (average 22.5 injec-
tions) regardless of anti-VEGF used in comparison with
PRN treatment (average 13.1 injection; p = 0.003) [12].
Further, Grunwald et al. [23] demonstrated that eyes
exhibiting SRF in the foveal centre were at lesser risk of
developing geographic atrophy than those without SRF by
2 years (when subretinal fluid thickness was >25 μm, the
aHR was 0.52 (95 % CI, 0.35-0.78)). Conversely, eyes with
IRF in the foveal centre (aHR, 2.10; 95 % CI, 1.34-3.31) or
away from it (aHR, 1.80; 95 % CI, 1.10-2.95) had a higher
risk of developing geographic atrophy compared with eyes
with no IRF [23].
What has become increasingly apparent is that pa-
tients show an individualised response to therapy and
opportunities to further optimise treatment need to be
explored and understood. The FLUID study (a phase IV,
randomised, controlled, single masked study investigat-
ing the efficacy and safety of ranibizumab T&E using an
intensive retinal fluid retreatment regimen compared to
a relaxed retinal fluid retreatment regimen in patients
with nAMD) has been implemented to address these
questions. This study will explore a T&E regimen by
testing the non-inferiority of a relaxed fluid management
approach (tolerance of any SRF unless specifically within
subfoveal area in which case only ≤ 200 µm SRF will be
tolerated) compared to an intensive fluid management
approach (no tolerance of SRF) as measured by the
mean change in best-corrected visual acuity (BCVA)
from baseline to 24 months. A range of pre-defined sec-
ondary endpoints will further our understanding of the
impact of variable treatment approaches, as well as
determining the influence of genotypes on treatment re-
sponse and outcomes. While current research is incon-
clusive as to the association between genotype and
treatment response, some studies have demonstrated
poorer visual outcome following ranibizumab or bevaci-
zumab therapy in patients expressing the homozygous
CC risk genotype at amino acid 402 of the CFH gene
and HTRA1 promoter SNP (rs11200638) and A69S at
LOC387715/ARMS2, as described by Brantley et al. [24]
and Abedi et al. [25], respectively.
The study hypothesis is that ranibizumab 0.5 mg when
administered to resolve IRF and/or SRF > 200 μm only at
the foveal centre (relaxed retinal fluid management) re-
sults in visual acuity benefit that is not clinically worse
than when administered to completely resolve both IRF
and SRF (intensive retinal fluid management) in patients
with nAMD.
This paper describes the methodology behind the
FLUID study and specific details of the T&E methodology.
Methods/Design
This is a multi-centre, randomised, two arm study being
conducted in 16 sites across Australia (http://clinical-
trials.gov/show/NCT01972789) [26]. A total of 347
nAMD patients have been recruited over an approximate
16 month period (30th October 2013 – 3rd March 2015).
This clinical study was designed, implemented and will
be reported in accordance with the International Confer-
ence on Harmonization (ICH) Harmonized Tripartite
Guidelines for Good Clinical Practice, with applicable
local regulations (including European Directive 2001/20/
EC, US Code of Federal Regulations Title 21, and Japa-
nese Ministry of Health, Labor, and Welfare) and with
the ethical principles laid down in the Declaration of
Helsinki. Ethics Approval has been obtained for all sites
within this study (Bellberry Limited Human Research
Ethics Committee for 13 sites (in New South Wales,
Victoria, South Australia, Western Australia, Tasmania),
Macquarie University Human Research Ethics Commit-
tee for one site (in New South Wales), The Royal Victor-
ian Eye and Ear Hospital Human Research Ethics
Committee for one site (in Victoria) and The Alfred
Ethics Committee for one site (in Victoria). Patients are
enrolled once written informed consent has been
obtained from patients by the Principal Investigator or
Sub-Investigator following full disclosure of the study
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and prior to any study related assessment or investiga-
tion is initiated.
A protocol amendment was made on 13th September
2013 to implement masking of the central reading centre
(being used to adjudicate on fluid status in patients), the
visual acuity assessor at study sites, and the patients. A
second protocol amendment was made on 11th February
2014 to address administrative anomalies, provide clari-
fication on some aspects of the methodology, implement
changes in the timing schedule for which certain study
procedures are to be performed, and modify exclusion
criteria to allow patients presenting with pseudoexfolia-
tion and add prohibitive treatments to the study eye. A
third protocol amendment was made on 10th December
2014 to remove the emergence of the following adverse
events – full thickness macular hole, stroke, myocardial
infarction, transient ischemic attack and rhegmatogen-
ous retinal detachment – from the list requiring a pa-
tient to be discontinued to the list for which
ranibizumab treatment be delayed until the condition is
successfully treated per investigator discretion. This was
implemented to bring the management of patients with
these conditions into alignment with standard clinical
practice. In addition, the amendment implemented alter-
ation of the procedure relating to the adjudication of ret-
inal fluid so that the sites are able to adjudicate on IRF
while the central reading centre continues to adjudicate
on SRF (outlined in detail below under the subtitle
“Masking”). A fourth protocol amendment was made on
12 October 2015 to clarify that IRF and intraretinal cysts
that, in the Investigator’s opinion, are likely to be recalci-
trant to anti-VEGF treatment are not considered in the
treatment protocol when making treatment extension
decisions to align with standard clinical practice. Further,
this amendment outlined the availability of ranibizumab
in the form of a pre-filled syringe.
The ranibizumab (Lucentis) administered in this study
is prescribed and dispensed via the Australian Pharma-
ceutical Benefits Scheme (PBS) and in compliance with
all regulatory and reimbursement requirements.
Inclusion and exclusion criteria
As outlined in Table 1, patients at least 50 years old with
a diagnosis of active subfoveal CNV secondary to nAMD
confirmed on fluorescein angiography (FA) in accord-
ance with PBS eligibility criteria and with evidence of
fluid on OCT with at least one treatment-naïve eye
meeting study criteria who are able to comply with study
requirements are being enrolled. Active CNV affecting
the fovea was defined on multi-modal imaging as subfo-
veal CNV (determined on FA) and, in addition, juxtafo-
veal or extrafoveal CNV where there was a component
of the CNV (ie fluid, SHRM) involving the fovea on
OCT. The presence of fluid (SRF and/or IRF) in the
study eye at baseline is not mandatory for inclusion of
patients into the trial.
While the study eye must be treatment-naïve, the
fellow eye may have been, or can be, treated with any
anti-angiogenic drug (including any anti-VEGF agents)
prior to baseline.
Patients must have a BCVA score of at least 23 let-
ters or more as measured by the 3 m (9.84 ft) Early
Treatment Diabetic Retinopathy Study (ETDRS) loga-
rithm of the minimum angle of resolution (logMAR)
charts (a Snellen visual acuity or equivalent of 20/320
can be alternatives). There is no upper limit to BCVA
eligibility.
The ocular exclusion criteria for the study eye include
visually significant cataract, aphakia, severe vitreous
haemorrhage, rhegmatogenous retinal detachment, pro-
liferative diabetic retinopathy or CNV of any other cause
than nAMD identified at the time of screening or base-
line. In addition, any structural damage within 0.5 disc
diameter of the centre of the macula (e.g. vitreomacular
traction, epiretinal membrane, scar, laser burn, foveal at-
rophy) at the time of screening that in the Investigator’s
opinion could preclude visual function improvement
with treatment is an exclusion criterion. Further, patients
treated with any anti-angiogenic drugs (including any anti-
VEGF agents) prior to baseline are excluded as are those
having any intraocular procedure (including Yttrium-
Aluminium-Garnet capsulotomy) within 2 months prior to
baseline or anticipated within the next 6 months following
baseline. Exclusion criteria applicable to both eyes include
any active periocular or ocular inflammation/infection, un-
controlled glaucoma on medication or neovascularisation
of the iris or neovascular glaucoma.
Patients with cardiovascular disease, including a history
of stroke or myocardial infarction less than 3 months prior
to screening, or an uncontrolled blood pressure defined as
systolic value of >160 mm Hg or diastolic value of
>100 mm Hg at screening or baseline cannot be enrolled.
Prohibited treatments include use of intra- or periocular
corticosteroids, or intraocular corticosteroid implants, as
are use of other investigational drugs and use of systemic
medications known to be toxic to the lens, retina or optic
Table 1 Key Inclusion Criteria
1. At least 50 years old.
2. Diagnosis of active subfoveal CNV secondary to nAMD confirmed on FA
in accordance with PBS eligibility criteria and with evidence of fluid on
OCT. Active CNV affecting the fovea was defined on multi-modal imaging
as subfoveal CNV (determined on FA) and, in addition, juxtafoveal or extra-
foveal CNV where there was a component of the CNV (ie fluid, SHRM) in-
volving the fovea on OCT.
3. At least one treatment-naïve eye.
4. BCVA score of at least 23 letters or more (Snellen visual acuity or
equivalent of 20/320).
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nerve as outlined in the Lucentis Australian Prescribing
Information [4] at any time during the study.
Endpoints
All efficacy assessments are performed on the study eye
(and, at certain time-points, on the fellow eye) and in-
clude both functional and anatomical evaluations. The
primary endpoint for the study is the mean change in
BCVA from baseline to month 24. The key secondary
endpoints are the mean change in BCVA from baseline
to month 12, the mean change in central retinal thick-
ness (CRT) from baseline to month 12 and 24, and the
mean number of injections from baseline to month 12
and 24. Additional secondary objectives include the pro-
portion of patients showing newly developed macular at-
rophy at months 12 and 24, mean change in area of new
and existing macular atrophy from baseline to month 12
and 24, proportion of patients showing no IRF and SRF
at months 2, 12 and 24, proportion of patients showing
≥15 ETDRS letter gain from baseline to month 12 and
24, proportion of patients showing < 15 ETDRS letter
loss from baseline to month 12 and 24, number of
rebounds back to monthly injections, determination of
genotypes associated with AMD or response to treat-
ment (and correlation of these genotypes with VA out-
come and ability to dry the retina), proportion of
patients with both SRF and IRF who despite monthly
treatment do not resolve their SRF as well as ocular and
systemic adverse events.
For the assessment of the presence of macular atrophy,
a multimodal imaging approach will be used. Image mo-
dalities will include fundus autofluorescence (AF) im-
aging, infrared imaging, OCT and colour fundus (CF)
photographs. Atrophy will be diagnosed if FA and one
other modality confirm the presence of macular atrophy.
For the determination of genotypes associated with
the response to treatment, this will be made not only
in terms of VA achieved and gain or loss of ETDRS
letters at month 12 and 24, but also in terms of the
ability to dry the retina of either (or both) IRF and
SRF after the first three monthly treatments of ranibi-
zumab or after the forth treatment of ranibizumab
(the first possible time for extension).
Treatment assignment and assessment
At baseline, patients were randomised 1:1 via an Inter-
active Web-based Response System (IWRS) to either an:
 Intensive retinal fluid treatment regimen (following the
initial 3 monthly injections of ranibizumab 0. 5 mg,
treatment interval is determined by disease activity,
aiming for complete resolution of all retinal fluid), or
 Relaxed retinal fluid treatment regimen (following
the initial 3 monthly injections of ranibizumab 0.
5 mg, treatment interval is determined by disease
activity, aiming for resolution of only IRF, and/or
≤200 µm of SRF; Fig. 1).
The IWRS (Balance) is integrated with the electronic
data capture (EDC) system (Medidata) and therefore site
personnel (Principal Investigator, Sub-Investigator or
Study Coordinator) access the IWRS through the EDC
system. Patient randomisation number and assignment
to treatment arm are provided by this IWRS/EDC
system.
For both treatment groups, all patients receive three
monthly injections of ranibizumab (0.5 mg in 0.05 mL)
at baseline, week 4 and week 8. Following the third in-
jection, the patient is assessed for disease activity in the
study eye as set out in Table 2 and determination of
treatment interval is made.
Treatment extension
In both arms, if any of these signs of activity are present
in the study eye, either singly or in combination, the
subsequent injection visit interval is kept at 4 weeks (i.e.
Fig. 1 OCT image showing presence of SRF (<200 μm height) within the subfoveal region of the macula that constitutes disease activity in the
Intensive retinal fluid arm only
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28 day interval; no increase in the treatment interval). If
none of these signs are present, the subsequent injection
interval is extended by 2 weeks, i.e. out to 6 weeks. This
process continues with 2 week extensions, as long as
there is no return of disease activity, until the maximum
retreatment interval of 12 weeks is reached. Once treat-
ment interval extension has occurred, the presence of
disease activity in the study eye requires a reduction in
the treatment interval as follows:
 If one sign of disease activity, as defined above, is
seen and the patient is currently on a 4 weekly
interval then the interval remains at 4 weeks.
 If one sign of disease activity, as defined above, is
seen and the patient is currently on a >4 weekly
interval then the interval is reduced by 2 weeks.
 If two (2), or more, signs of disease activity, as
defined above, are seen then the interval of
injections reverts back to 4 weekly injections.
The interval is further decreased by 2 weeks (if the
interval is not currently at 4 weeks) at the subsequent
visit(s) if signs of activity continue to be detected using
this approach. Extension will again occur at a subse-
quent visit if there are no signs of disease activity. How-
ever, after the second attempt at extension, any further
attempts will have the maximum interval of 2 weeks less
than the interval at which activity previously re-occurred
(referred to as the break point). If the patient was
returned to 4 weekly intervals on the first extension and
again on the second extension, then no more attempts
at extension will occur during the study.
To align with real-world scenarios typical in stand-
ard clinical practice, there are no specific withdrawal
criteria that relate to vitrectomy or other surgical in-
traocular procedures (other than use of anti-VEGF,
corticosteroid or investigational drugs/interventions)
once ranibizumab treatment has commenced. Full
thickness macular hole, stroke, myocardial infarction,
transient ischemic attack and rhegmatogenous retinal
detachment require a delay in ranibizumab treatment
until the condition is successfully treated per investi-
gator discretion.
Protocol visits
Patients will undergo assessment of BCVA and OCT at
all visits in the study eye. BCVA with refraction and both
CF and FA will be performed only at screening/baseline,
month 12 and month 24 visits in the study eye (in
addition, BCVA with refraction will be performed at the
month 2 visit). These same assessments will occur in the
fellow eye at screening/baseline, month 12 and month
24 only. The FA images are evaluated by the central
reading centre to determine the presence and type of
AMD and area of leakage of the CNV.
VA is performed using a logMAR chart at a distance
of 3 m at all visits (this distance was specifically chosen
to accommodate the average room size for many sites).
If it is not possible to perform a subjective refraction or
VA testing due to any reason, the refraction/visual acuity
testing is attempted at a distance of 1 m. OCT images
are taken at all visits after the BCVA assessment and be-
fore any injection procedure using High Definition
(HD)/Spectral Domain (SD) OCT equipment. AF is op-
tional at sites based on availability of equipment at each
site and is performed to measure the presence of exist-
ing macular atrophy in the study at screening/baseline
and week 8, and the expansion of existing macular atro-
phy and newly developed macular atrophy at month 12
and 24. For all procedures, the relevant investigational
site personnel are certified by the accredited vendors
(Klinitrial for VA and the Bern Photographic Reading
Center for OCT, FA, CF, AF) prior to commencement of
assessments.
The maximum number of patient visits is 26 (assum-
ing monthly visits throughout and separate screening
and baseline visits) while the minimum number of pa-
tient visits is 13 (assuming extension to 12 weeks with
no breaks and separate screening and baseline visits).
After completion of the study, patients will return to the
standard care of each clinician.
Masking
To ensure that the primary endpoint measurement of
BCVA score is not influenced by bias, both the BCVA
assessor and the patient are masked to the treatment as-
signment. Further, to avoid the introduction of Investiga-
tor bias in making retreatment decisions (since the
Investigator is both the assessor and injector at the ma-
jority of sites), a central reading centre (Bern Photo-
graphic Reading Center, Bern, Switzerland) is employed
to mask the study and facilitate compliance of Investiga-
tor sites to the protocol. The central reading centre is
masked to the randomisation and treatment of the pa-
tient. All images collected during the study (OCT, FA,
CF, AF) are sent to the central reading centre for ana-
lysis. Since the primary aim of the study is to investigate
whether retreatment should be based on SRF, masked
Table 2 Criteria for Disease Activity
1. A loss of VA ≥5 letters than the best VA recorded since baseline.
2. New retinal haemorrhage.
3. The presence of IRF or SRF on OCT.
For patients in the Intensive retinal fluid arm, this criterion is “the
presence of any IRF or SRF”.
For patients in the Relaxed retinal fluid arm, this criterion is “the
presence of any IRF or SRF >200 μm in height at subfoveal centre”
(as measured by the caliper function on the OCT). Sub-RPE fluid does
not constitute part of the decision-making criteria for either arm.
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reading centre assessment of the presence of SRF over-
rides investigator assessment in determining retreatment
interval. While the reading centre will read the IRF com-
ponent as well, the investigator is allowed discretion if
they disagree with the reading centre's interpretation of
the IRF component. The adjudication of IRF by the in-
vestigator site was implemented by a protocol amend-
ment (3) on 10th December 2014 to ensure greater
alignment with standard clinical practice since decisions
on IRF often cannot be made in isolation (as is the case
with a central reading centre assessment) i.e. requiring
more than OCT plus an assessment of the patient’s pre-
vious response to anti-VEGF therapy to determine if
spaces on the OCT are indicative of active disease or, al-
ternatively, if they represent chronic atrophic changes.
This change does not impact the key study question,
which is whether SRF needs to be completely resolved in
making treatment extension decisions since the adjudica-
tion of SRF remains with the central reading centre. The
original protocol (and protocol amendments 1 and 2)
required that IRF adjudication be performed only by the
masked reading centre.
Statistical analyses
The sample size for non-inferiority is based on a one-
sided t-test with α = 0.025 and 80 % power. For the non-
inferiority estimate, the ranibizumab T&E relaxed fluid
management arm will be assessed against the ranibizu-
mab T&E intensive fluid management arm and consid-
ered non-inferior if the lower limit of the 95 % two sided
confidence interval for the difference in changes from
baseline BCVA is greater than the negative margin; i.e.
the lower limit of the 95 % confidence interval for the
difference in change in BCVA score is greater than - 5.
This non-inferiority margin of 5 BCVA letters is consist-
ent with that used previously in the landmark CATT
study which investigated the effects of anti-VEGF ther-
apies on nAMD [11] and represents a clinically mean-
ingful change in vision. Applying a standard deviation of
15 letters and accounting for a 15 % drop out rate dur-
ing the 24 month study duration (both used in the
CATT study [11]), the minimum number of patients re-
quired per arm for mean change in BCVA score is 165 pa-
tients. Unless otherwise specified in the Statistical
Analysis Plan, for which greater details will be provided in
subsequent publication of the FLUID results, the intent-
to-treat principle will be used for the primary, secondary
and pre-specified exploratory efficacy analyses.
The FLUID study is fully recruited with a total of 347
patients having been recruited in 16 Australian sites
located throughout New South Wales, Victoria,
Tasmania, South Australia and Western Australia. One
hundred and seventy three (173) patients were rando-
mised to the Intensive retinal fluid arm and 174 patients
were randomised to the Relaxed retinal fluid arm. Enrol-
ment commenced on 30th October 2013 and was com-
pleted on 3rd March 2015 (~16 month period) (Fig. 2).
Full data analysis will be reported by the end of 2017.
Baseline demographic outcomes and primary and second-
ary outcomes will be presented in future publications.
Discussion
Globally, over 90 % of retinal specialists use an indivi-
dualised approach (either PRN or T&E) in treating their
Fig. 2 Flow chart outlining patient enrollment and allocation for study
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nAMD patients with anti-VEGF therapy [19]. As such,
each physician is required to make a judgment on the ac-
tivity of the CNV lesion. The current best clinical practice
states that fluid on an OCT will be considered as an indi-
cation of active disease. However, we know that physicians
add their own interpretation to the appearance of fluid
and make a judgment call on its relevance to disease activ-
ity. For example, they question whether a cyst is a chronic
atrophic cyst, or whether SRF is simply a failure of the
interdigitating photoreceptors and RPE to reconnect
tightly thus leaving a small “space”. All of these anatomical
features would be interpreted by a reading centre as evi-
dence of fluid and therefore disease activity yet, in many
instances, clinicians would not act on these findings. In-
deed, in the CATT study, there was a discrepancy of fluid
interpretation between the reading centre and investiga-
tors in 31 % of adjudications in which the reading centre
found fluid where the clinician did not (and thus did not
treat with anti-VEGF therapy) [12].
Therefore, there appears to be an “art” based on years of
experience that informs a clinician as to the relevance of
certain appearances of fluid and how it has behaved with
previous treatments when making their decision to treat
in the case of PRN protocols, or extend an interval in the
case of T&E protocols. Our research in the FLUID study
aims to address these unscripted decisions in order to help
all clinicians who are now attempting to make judgments
on disease activity for their patients presenting with
nAMD. The key question being addressed in the study is
whether or not a small amount of SRF (≤200 μm) still
present at the end of the often-implemented three initial
monthly injections is a variable that affects final VA or,
alternatively, if remaining SRF is not associated with worse
visual outcomes. Note that the figure of 200 μm was
chosen as the upper limit of tolerance for SRF by the study
Steering Committee who made the clinical judgement that
an accumulation of SRF less than this was acceptable to
investigators to not actively treat. In addition, 200 μm was
deemed sufficiently large to be reproducibly measured by
both site and the central reading centre. If the study does
not demonstrate any difference in visual outcomes be-
tween the two arms, that is, if there is no difference in VA
at 24 months between the relaxed fluid treatment regimen
compared to the intensive fluid treatment regimen, then it
would suggest that clinicians may adopt a treatment ap-
proach in which less ranibizumab injections are required
to still achieve optimal visual outcomes. It will also high-
light the notion that a clinician’s experience in inter-
preting OCT findings is a crucial factor in achieving
optimal outcomes for that individual patient. The more
we can articulate what this experience tells us by way of
protocols, the easier it will be for clinicians with less
experience in this disease to achieve optimal visual out-
comes while minimising treatment burden.
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